Author:
Alacevich Caterina,Abi Nehme Anna Maria,Lee Ji-Hyun,Li Derek,Mobley Erin M.,Close Julia L.,George Thomas J.,LeLaurin Jennifer H.,Hong Young-Rock,Shenkman Elizabeth A.,Gutter Michael S.,Salloum Ramzi G.
Funder
National Center for Advancing Translational Sciences
University of Florida Health Cancer Center
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Soni A (2009) The five most costly conditions, 1996 and 2006: estimates for the US civilian noninstitutionalized population. Statistical brief# 248. https://www.bmedreport.com/archives/7231. Accessed 1 Feb 2023
2. Shih YCT, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ (2015) Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol 33(19):2190. https://doi.org/10.1200/JCO.2014.58.2320
3. Yabroff KR et al (2021) Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care. J Natl Cancer Inst 113(12):1670–1682. https://doi.org/10.1093/JNCI/DJAB192
4. Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68(2):153–165. https://doi.org/10.3322/CAAC.21443
5. Lentz R, Benson AB, Kircher S (2019) Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol 120(1):85–92. https://doi.org/10.1002/JSO.25374
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献